TCRX logo

TCRX
Tscan Therapeutics Inc

874
Mkt Cap
$72.72M
Volume
1.28M
52W High
$2.57
52W Low
$0.8824
PE Ratio
-1.32
TCRX Fundamentals
Price
$1.26
Prev Close
$1.21
Open
$1.23
50D MA
$1.12
Beta
1.39
Avg. Volume
1.33M
EPS (Annual)
-$0.9999
P/B
0.78
Rev/Employee
$72,711.27
$71.51
Loading...
Loading...
News
all
press releases
TScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Hits Expectations
TScan Therapeutics (NASDAQ:TCRX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.22). TScan Therapeutics had a negative net margin of 1,256.81% and a negative return on...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +1.12% and -57.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Brokerages
TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has earned a consensus recommendation of "Hold" from the six research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recom...
MarketBeat·4d ago
News Placeholder
TScan Therapeutics (TCRX) Expected to Announce Quarterly Earnings on Tuesday
TScan Therapeutics (NASDAQ:TCRX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...
MarketBeat·11d ago
News Placeholder
TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Analysts
TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has been assigned an average recommendation of "Hold" from the six analysts that are presently covering the stock, MarketBeat reports. One...
MarketBeat·29d ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Shares Up 3% - Here's What Happened
TScan Therapeutics (NASDAQ:TCRX) Stock Price Up 3% - Here's What Happened...
MarketBeat·1mo ago
News Placeholder
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care PR Newswire VANCOUVER, BC, March 19, 2026...
PR Newswire·2mo ago
News Placeholder
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages
Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been assigned an average rating of "Hold" from the six brokerages that are currently covering the stock, Marketbeat.com...
MarketBeat·2mo ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen cut TScan Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·2mo ago
News Placeholder
HC Wainwright Issues Positive Outlook for TCRX Earnings
TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - HC Wainwright raised their Q1 2026 earnings estimates for TScan Therapeutics in a research note issued on Wednesday, March 4th. HC Wainwright...
MarketBeat·2mo ago
<
1
2
...
>

Latest TCRX News

View
Top Discussions